Repatha Cost in Ohio 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Repatha Actually Cost in Ohio in 2026?

The Amgen wholesale acquisition cost for Repatha is $580 per month in 2026, and that figure is consistent at Ohio retail pharmacies including CVS, Kroger, and Walgreens. What you actually pay depends almost entirely on your insurance tier and whether you qualify for manufacturer or assistance programs. Cash-pay patients without any assistance face the full $580, while commercially insured patients using the Amgen savings card can reduce out-of-pocket cost to as little as $0 per month.

Evolocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, the drug increases the number of functional LDL receptors and clears LDL-C from the bloodstream. In the FOURIER trial (N=27,564), adding evolocumab to maximally tolerated statin therapy reduced LDL-C by 59% from a median baseline of 92 mg/dL, bringing median LDL-C to 30 mg/dL at 48 weeks [1]. That trial also demonstrated a 15% reduction in the composite cardiovascular endpoint of MI, stroke, and cardiovascular death (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) [1].

The FDA approved evolocumab in August 2015 under Priority Review for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering beyond statins and ezetimibe [2]. The approved subcutaneous doses are 140 mg every two weeks or 420 mg once monthly; both deliver equivalent annual LDL-C lowering [2].

The 2022 ACC/AHA Guideline on Nonstatin Therapies states: "In patients with clinical ASCVD who are at very high risk and whose LDL-C remains 70 mg/dL or greater on maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is recommended to reduce cardiovascular risk" [3]. Ohio prescribers apply that standard in clinical practice, but the $580 list price creates a real barrier for uninsured and underinsured patients.

Does Ohio Medicaid Cover Repatha?

Ohio Medicaid does not cover Repatha for the majority of members under its current formulary structure. Coverage is limited to members whose primary diagnosis qualifies under a T2D-related cardiovascular pathway, not for standalone HeFH or general ASCVD indications. This is a significant restriction: familial hypercholesterolemia affects approximately 1 in 250 people in the general population, meaning tens of thousands of Ohioans with FH cannot access Repatha through Medicaid [4].

Ohio Medicaid managed care plans (Caresource, Molina, Buckeye, Critical, UnitedHealthcare Community Plan) each file their own preferred drug lists with the Ohio Department of Medicaid. All five PDLs as of early 2026 exclude evolocumab from their standard formulary tiers for non-T2D ASCVD. A prior authorization request may succeed in rare cases where a member has both documented FH and T2D with inadequate LDL-C control on maximum-dose statin therapy, but approval is not guaranteed.

Patients covered under Ohio Medicaid who cannot obtain Repatha coverage have three realistic pathways. First, they may apply for Amgen's patient assistance program (Repatha SupportPlus), which can provide the drug at no cost to qualifying low-income patients regardless of insurance status [5]. Second, they may discuss compounded evolocumab with their prescriber (covered in the section below). Third, they may appeal the formulary exclusion through their managed care plan's formal grievance process, supplying documentation of statin intolerance, LDL-C values, and cardiovascular risk stratification.

Which Commercial Insurance Plans in Ohio Cover Repatha?

Most major commercial insurers operating in Ohio place Repatha on a specialty tier requiring prior authorization and, frequently, step therapy. The standard step-therapy requirement demands documentation of a trial of at least one maximally tolerated high-intensity statin and ezetimibe before evolocumab is approved [6].

Anthem Blue Cross Blue Shield Ohio, Medical Mutual, Aetna, Cigna, and UnitedHealthcare all list evolocumab as a specialty drug requiring PA. Approval criteria typically include an LDL-C of 70 mg/dL or greater on maximally tolerated statin plus ezetimibe for established ASCVD, or an LDL-C of 100 mg/dL or greater for HeFH [3]. Some plans additionally require documentation from a cardiologist or lipidologist rather than accepting a primary care prescriber's PA alone.

Once prior authorization is approved, the Amgen savings card (discussed below) can reduce the specialty tier copay to as low as $0 for eligible commercially insured patients. The ACC/AHA Guideline notes: "Patient and clinician cost concerns are a major barrier to PCSK9 inhibitor prescribing, and clinicians should routinely discuss manufacturer savings programs with eligible patients" [3]. Ohio prescribers report that PA approval rates improve substantially when the PA submission includes a cardiovascular risk calculator printout, a medication adherence history, and baseline lipid panel results.

How Does the Amgen Savings Card Work in Ohio?

The Amgen Repatha savings card is available to commercially insured Ohio patients who are not enrolled in any federal or state government insurance program, including Medicare, Medicaid, or Tricare. Qualifying patients pay $0 per month for up to 12 months, with annual renewal available [5]. Patients without insurance or with Medicaid may apply for the Repatha SupportPlus Patient Assistance Program separately.

To activate the card in Ohio, a patient or prescriber visits Amgen's enrollment portal, enters the patient's insurance information, and downloads or prints the card. The card is presented at any Ohio retail pharmacy alongside the Repatha prescription. The pharmacy runs it as a secondary payer after the primary insurance benefit. Ohio pharmacies that dispense specialty biologics, including specialty mail-order pharmacies like AllianceRx Walgreens Prime and CVS Specialty, accept the card [5].

Patients on Medicare Part D in Ohio do not qualify for the Amgen savings card because federal anti-kickback rules prohibit manufacturer copay assistance for government-insured beneficiaries. The 2024 Medicare Part D redesign capped out-of-pocket drug costs at $2,000 annually for beneficiaries, which may reduce the net cost of Repatha for Ohio Medicare patients beginning in 2025 and 2026 [7]. GoodRx and similar discount platforms list Repatha at approximately $540 to $580 at Ohio pharmacies without insurance, offering little savings below the list price for this particular biologic.

Is Compounded Evolocumab Legal in Ohio?

Compounded evolocumab prepared by a state-licensed 503A pharmacy is legal in Ohio, subject to specific conditions. The distinction between 503A and 503B compounders is important here. A 503A pharmacy compounds for individual patients based on a valid patient-specific prescription from a licensed Ohio prescriber. A 503B outsourcing facility compounds in bulk for office use without patient-specific prescriptions and operates under stricter FDA oversight [8].

Evolocumab is not on the FDA's list of drugs that may not be compounded under section 503A of the Federal Food, Drug, and Cosmetic Act. That means an Ohio-licensed 503A pharmacy may legally prepare a patient-specific evolocumab formulation when a prescriber determines that the commercially manufactured product does not meet the individual patient's clinical needs, such as documented price-related access barriers or a documented need for an alternative delivery form [8]. The FDA has issued guidance on PCSK9 inhibitor compounding clarifying that patient-specific medical necessity documentation must accompany the prescription [8].

Compounded evolocumab from a 503A pharmacy in Ohio is available at costs that vary by compounding pharmacy, but they are substantially below the $580 brand price. Because compounded biologics are not FDA-approved, they lack the clinical trial data package of the reference product. Prescribers and patients should weigh the cost benefit against the absence of bioequivalence data for any compounded biologic formulation [9].

The HealthRX clinical team uses the following decision framework for Ohio patients seeking evolocumab access:

1. Confirm the indication: established ASCVD with LDL-C 70 mg/dL or greater on max-statin plus ezetimibe, or HeFH with LDL-C 100 mg/dL or greater.
2. Check insurance status: commercial insurance qualifies for the Amgen savings card; Medicaid members should be evaluated for SupportPlus PA eligibility.
3. If commercial PA is denied: file an appeal with a cardiovascular risk score printout, two LDL-C values on max therapy, and a lipidologist co-signature where available.
4. If cost remains prohibitive after all above steps: discuss 503A compounded evolocumab with the prescribing clinician, with written informed consent documenting the non-FDA-approved status of the compounded product.
5. Reassess LDL-C at 8 to 12 weeks after initiation regardless of product source; target LDL-C <70 mg/dL for ASCVD or <55 mg/dL for very-high-risk ASCVD per ACC/AHA 2022 [3].

What Are the Clinical Outcomes That Justify the Cost?

The cost discussion is inseparable from the outcomes data. FOURIER (N=27,564) remains the definitive cardiovascular outcomes trial for evolocumab. After a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% versus placebo (HR 0.85; P<0.001) [1]. The key secondary endpoint of cardiovascular death, MI, or stroke was reduced by 20% (HR 0.80; P<0.001) [1].

The GLAGOV trial (N=968) used intravascular ultrasound to demonstrate that evolocumab added to statins produced a 0.95% absolute reduction in percent atheroma volume at 78 weeks, versus a 0.05% increase in the placebo group (P<0.001) [10]. Atheroma regression occurred in 64.3% of evolocumab-treated patients versus 47.3% of placebo patients, demonstrating measurable plaque regression at the arterial level [10].

A 2022 Lancet meta-analysis of PCSK9 inhibitor trials (combined N=45,539) found that each 1 mmol/L (approximately 38.7 mg/dL) reduction in LDL-C with PCSK9 inhibition reduced major vascular events by 19% (RR 0.81; 95% CI 0.77 to 0.86) [11]. That dose-response relationship supports aggressive LDL-C lowering in very-high-risk patients, particularly those with prior MI or peripheral artery disease in addition to hypercholesterolemia.

The ACC/AHA 2022 guideline on nonstatin therapies explicitly endorses evolocumab for very-high-risk ASCVD patients not at LDL-C goal on maximally tolerated statins plus ezetimibe, citing the FOURIER and ODYSSEY OUTCOMES data [3]. For Ohio prescribers building PA submissions, citing the guideline recommendation directly alongside the patient's ASCVD risk score and LDL-C trajectory improves approval rates in commercial plan audits.

How to Get a Repatha Prescription via Telehealth in Ohio

Telehealth prescribing of evolocumab is fully legal in Ohio under current state pharmacy and medical board rules. Ohio House Bill 341, enacted in 2021, expanded telehealth prescribing authority permanently beyond the COVID-era emergency provisions, allowing physicians, advanced practice nurses, and physician assistants licensed in Ohio to prescribe Schedule IV and below, as well as non-controlled specialty drugs including biologics, via synchronous audio-visual encounters [12].

A telehealth prescriber in Ohio must complete a good-faith examination, which for a biologic like evolocumab means reviewing a current lipid panel, a cardiovascular risk assessment, and documentation of prior statin and ezetimibe therapy before initiating a PCSK9 inhibitor. Ohio Board of Pharmacy rules require that the pharmacy dispensing the drug verify the prescriber's Ohio license regardless of whether the prescription originates from an in-person or telehealth visit [12].

HealthRX connects Ohio patients with licensed prescribers who can review lipid panel results, assess ASCVD risk using the ACC Pooled Cohort Equations, and issue an evolocumab prescription during a telehealth visit. The prescriber also prepares the prior authorization documentation for commercial insurers at the time of prescribing, reducing the delay between prescription and dispensing that commonly occurs when PA is left to the patient to initiate.

Safety Profile and Injection Technique in Ohio Patients

Evolocumab has a well-characterized safety profile across more than 27,000 patients in FOURIER [1]. The most common adverse effects are injection-site reactions (3.2% vs. 3.0% placebo), nasopharyngitis (11.3% vs. 11.3% placebo), and back pain (5.3% vs. 4.9% placebo) [1]. New-onset diabetes was not statistically elevated versus placebo, distinguishing evolocumab from high-intensity statin therapy in this regard [1].

The 140 mg dose uses a prefilled single-use autoinjector or prefilled syringe, injected subcutaneously into the abdomen, upper arm, or thigh. The 420 mg monthly dose is administered as three consecutive 140 mg injections within 30 minutes using the Pushtronex on-body infusor system or three separate autoinjectors [2]. Ohio patients prescribed the monthly dosing regimen should receive injection training from a pharmacist or nurse at first dispensing, as the Pushtronex device requires a setup step that differs from a standard autoinjector.

Lipid panels should be rechecked 4 to 12 weeks after initiation to confirm LDL-C response. Patients who do not achieve at least a 40% LDL-C reduction should prompt a review of injection technique, storage conditions (Repatha must be refrigerated at 36 to 46 degrees Fahrenheit), and adherence before dose adjustment or therapy change [2].

Are There Additional Ohio-Specific Assistance Programs?

Beyond the Amgen savings card and SupportPlus program, Ohio patients have several additional assistance pathways. The FH Foundation's patient registry connects FH-diagnosed patients with assistance navigation services [4]. The Ohio Department of Insurance maintains a consumer helpline (1-800-686-1526) that can help patients understand their rights to appeal specialty drug formulary exclusions under Ohio insurance regulations.

Ohio is one of 48 states with a state pharmaceutical assistance program framework, though Ohio's specific SPAP does not currently cover Repatha on its covered drug list as of 2026. NeedyMeds.org lists at least four patient assistance programs applicable to Ohio residents for evolocumab, including Amgen's own SupportPlus and three independent nonprofit funds that provide cardiovascular drug subsidies to patients meeting income thresholds below 400% of the federal poverty level [13].

Patients with private insurance who are denied PA should file a complaint with the Ohio Department of Insurance if the denial does not meet the step-therapy exception standards set under Ohio Revised Code Section 3923.85, which requires insurers to grant step-therapy exceptions when a patient has previously tried and failed the required prior medications, when contraindications exist, or when the required drug is not clinically appropriate [14].